MiMedx Group (MDXG): Valuation Insights Following Record Q3 Results and Upgraded 2025 Outlook

MiMedx Group reported its third quarter 2025 results, showing sharp growth in both sales and profits compared to last year. The company also raised its full-year revenue growth outlook. This reflects strong momentum in key business areas.

See our latest analysis for MiMedx Group.

MiMedx Group’s upbeat Q3 results and raised revenue guidance have clearly caught the market’s attention, helping power a 13% seven-day share price return and reversing much of the year-to-date decline. While short-term volatility has been noticeable, the company’s one-year total shareholder return of 10% and a remarkable 158% total return over three years reflect the longer-term momentum building behind the stock.

If you’re looking for more growth stories among healthcare innovators, check out See the full list for free..

With shares rebounding sharply and the company now trading at a significant discount to analyst targets, investors must ask whether the upbeat outlook leaves room for further upside or if expectations are already fully priced in.

Most Popular Narrative: 37.3% Undervalued

MiMedx Group’s most widely followed narrative pegs fair value at $12.20 per share, substantially above the last close at $7.65. This wide gap spotlights a sharply optimistic reading on the company’s current trajectory and future catalysts.

"Ongoing expansion of the product portfolio, including new skin substitutes, surgical allografts, complementary devices, and collaborations, creates multiple avenues for revenue growth and market share gains, reducing concentration risk and supporting earnings over the long-term."

Read the complete narrative.

Want to know what’s fueling this bold upside? The assumptions behind this fair value hinge on ambitious growth projections and surprisingly strong margin targets. Analysts are betting on multiple expansion levers. Can MiMedx deliver? Get the numbers and see what’s driving the optimism in the full narrative.

Result: Fair Value of $12.20 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, looming Medicare reimbursement changes and risks from increased competition could undermine the bullish outlook and dampen the growth trajectory of MiMedx Group.

Find out about the key risks to this MiMedx Group narrative.

Build Your Own MiMedx Group Narrative

Feel free to dive into the data, challenge the consensus, and shape your own take on MiMedx Group’s story in just a few minutes. Do it your way.

A great starting point for your MiMedx Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Ready to Find Your Next Investment Win?

Miss out on your next portfolio breakout by hesitating now. Push your investing forward and check fresh ideas using Simply Wall Street’s powerful screeners.

• Capture growth potential in the tech space when you check out these 26 AI penny stocks driving innovation and reshaping tomorrow’s industries.
• Unlock income opportunities and add stability to your holdings with these 22 dividend stocks with yields > 3% offering yields above 3% and strong payout histories.
• Stay ahead of the curve with these 28 quantum computing stocks at the forefront of quantum computing, where breakthroughs could transform entire sectors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com